Alex Azar And The Return Of Republican-Style Price Negotiation
Executive Summary
The nomination of a former drug industry executive to run HHS is obviously good news for the biopharma sector, but it does not mean that HHS will do nothing about drug prices. On the contrary, it may make some high-profile action against pricing outliers all but inevitable.
You may also be interested in...
Trump Expecting Rx Price Reduction Announcements In Two Weeks
Look for Administration to take credit for any positive pricing news as President says several firms will 'announce voluntary massive drops in prices.'
The Spectacle Of Trump: Tweets, Insults And A Year Pharma Won't Forget
From "getting away with murder" to "rip-off drug prices," pharma had its share of face-offs with President Trump in 2017. In the end, industry appears to have fared well under the pro-business leader, with industry insider Alex Azar now heading HHS and corporate tax reform a new year treat for industry.
HHS Nominee Azar And The Taint Of Industry
During the first step of the confirmation process, HHS Secretary nominee Alex Azar did a good job of framing his industry background as useful experience for tackling drug prices. But wouldn’t it be nice if everyone agreed that 10 years as Lilly was something to be proud of?